Recent News

  1. Jubilant Receives Favorable Ruling from the U.S. Courts for RUBY-FILL®   Yardley, PA, December 11, 2019 – On December 2, 2019, Jubilant DraxImage Inc. and certain of its affiliates (“Jubilant”) received notice of the favorable decision of the U.S. International Trade Commission (the “ITC”) in its case against Bracco Diagnostics (...)
  2. Dear Valued RUBY-FILL User, Please find here an important drug safety communication, as requested by the FDA, regarding the potential risk to high-level radiation exposure in some patients due to Sr-82 and Sr-85 breakthrough in the eluate when using an incorrect solution to elute a Rubidium Rb-82 generator and failure (...)
  3. We are pleased to announce that we have partnered with other industry leaders on a joint industrial communication to the nuclear medicine community in an effort to raise awareness regarding the potential supply of non-FDA approved products to their institutions.    
  4. Jubilant DraxImage recently participated in the Family Health Campaign in which we joined industry advocates, leaders and professionals to raise awareness of the continuously growing impact of cardiovascular disease and the growing number of deaths associated with it – 1 in 4 deaths in the U.S. is caused by heart disease and (...)
  5. Legal action from Bracco Diagnostics, Inc. regarding patent infringement Montreal, QC, April 4, 2018 – Jubilant DraxImage Inc. (“DraxImage”), recently learned of legal challenges filed by Bracco Diagnostics, Inc. (“Bracco“) including a complaint filed with the U.S. International Trade Commission (ITC) regarding alleged patent infringement related to the Jubilant DraxImage (...)
  6. Jubilant DraxImage receives approval for new pulmonary indications from the U.S. Food and Drug Administration for DRAXIMAGE® DTPA Montreal, QC, December 27 2017 – Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma wholly-owned subsidiary, is pleased to announce approval of new pulmonary indications for DRAXIMAGE® DTPA (Kit for the Preparation of Technetium (...)